BioM2MetDisease: a manually curated database for associations between microRNAs, metabolites, small molecules and metabolic diseases
暂无分享,去创建一个
Fei Su | Xia Li | Feng Li | Yunpeng Zhang | Yingqi Xu | Yanjun Xu | Haixiu Yang | Desi Shang | Zeguo Sun | Tan Wu | Qun Dong | Siyao Liu | Xia Li | Yunpeng Zhang | Yanjun Xu | Feng Li | Zeguo Sun | Tan Wu | Siyao Liu | Haixiu Yang | Fei Su | Yingqi Xu | Qun Dong | D. Shang | F. Su
[1] Chris Sander,et al. An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. , 2016, Cancer cell.
[2] Eric J. Brunner,et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study , 2014, European heart journal.
[3] Hyun-Young Park,et al. Metabolic markers associated with insulin resistance predict type 2 diabetes in Koreans with normal blood pressure or prehypertension , 2016, Cardiovascular Diabetology.
[4] Xia Li,et al. Comprehensive analysis of the functional microRNA–mRNA regulatory network identifies miRNA signatures associated with glioma malignant progression , 2013, Nucleic acids research.
[5] Johan Auwerx,et al. Protein acetylation in metabolism — metabolites and cofactors , 2016, Nature Reviews Endocrinology.
[6] D. Bartel. MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.
[7] D. Bartel,et al. Predicting effective microRNA target sites in mammalian mRNAs , 2015, eLife.
[8] Sarah Spiegel,et al. Sphingosine-1-phosphate signaling and its role in disease. , 2012, Trends in cell biology.
[9] Athanasios Fevgas,et al. DIANA-miRGen v3.0: accurate characterization of microRNA promoters and their regulators , 2015, Nucleic Acids Res..
[10] Inhye Park,et al. Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development , 2015, Proceedings of the National Academy of Sciences.
[11] Dragan M. Svrakic,et al. Depression in Type 2 Diabetes Mellitus: Prevalence, Impact, and Treatment , 2015, Drugs.
[12] C. Harris,et al. Biomarker development in the precision medicine era: lung cancer as a case study , 2016, Nature Reviews Cancer.
[13] Peter Arner,et al. MicroRNA regulatory networks in human adipose tissue and obesity , 2015, Nature Reviews Endocrinology.
[14] Fabian J Theis,et al. PhenomiR: a knowledgebase for microRNA expression in diseases and biological processes , 2010, Genome Biology.
[15] Sung Hee Choi,et al. Increasing Prevalence of Metabolic Syndrome in Korea , 2011, Diabetes Care.
[16] JoAnn E. Manson,et al. Genetic Predisposition to Central Obesity and Risk of Type 2 Diabetes: Two Independent Cohort Studies , 2015, Diabetes Care.
[17] Hsien-Da Huang,et al. miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database , 2015, Nucleic Acids Res..
[18] David S. Wishart,et al. HMDB 3.0—The Human Metabolome Database in 2013 , 2012, Nucleic Acids Res..
[19] Manuel Mayr,et al. MicroRNAs in vascular and metabolic disease. , 2012, Circulation research.
[20] A. Näär,et al. MicroRNAs in metabolism and metabolic disorders , 2012, Nature Reviews Molecular Cell Biology.
[21] Stefan Offermanns,et al. Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes , 2015, Nature Medicine.
[22] Gang Fu,et al. PubChem Substance and Compound databases , 2015, Nucleic Acids Res..
[23] Ana Kozomara,et al. miRBase: annotating high confidence microRNAs using deep sequencing data , 2013, Nucleic Acids Res..
[24] Peng Wang,et al. Lnc2Cancer: a manually curated database of experimentally supported lncRNAs associated with various human cancers , 2015, Nucleic Acids Res..
[25] Andreas Kowarsch,et al. PhenomiR: microRNAs in human diseases and biological processes. , 2012, Methods in molecular biology.
[26] Marc Prentki,et al. Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes , 2015, Diabetes.
[27] Ning Liang,et al. Loss of the co-repressor GPS2 sensitizes macrophage activation upon metabolic stress induced by obesity and type 2 diabetes , 2016, Nature Medicine.
[28] Yadong Wang,et al. miR2Disease: a manually curated database for microRNA deregulation in human disease , 2008, Nucleic Acids Res..
[29] Wanchang Lin,et al. Untargeted metabolic profiling identifies altered serum metabolites of type 2 diabetes mellitus in a prospective, nested case control study. , 2015, Clinical chemistry.
[30] Nicolás Peláez,et al. Biological robustness and the role of microRNAs: a network perspective. , 2012, Current topics in developmental biology.
[31] Artemis G. Hatzigeorgiou,et al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support , 2015, Nucleic Acids Res..
[32] Athanasios Fevgas,et al. DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions , 2014, Nucleic Acids Res..
[33] Yang Li,et al. HMDD v2.0: a database for experimentally supported human microRNA and disease associations , 2013, Nucleic Acids Res..
[34] David S. Wishart,et al. DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..
[35] Vladimir B. Bajic,et al. FARNA: knowledgebase of inferred functions of non-coding RNA transcripts , 2016, Nucleic acids research.
[36] Choon Nam Ong,et al. Acetylcarnitine Is a Candidate Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma. , 2016, Cancer research.
[37] Xing Chen,et al. LncRNADisease: a database for long-non-coding RNA-associated diseases , 2012, Nucleic Acids Res..
[38] A. Tahrani,et al. Novel therapeutics for type 2 diabetes: insulin resistance , 2015, Diabetes, obesity & metabolism.